clinvestКачественная клиническая практикаKachestvennaya Klinicheskaya Praktika = Good Clinical Practice2588-05192618-8473ООО «Издательство ОКИ10.37489/2588-0519-2024-3-80-83THZBOTclinvest-746Research ArticleИССЛЕДОВАНИЯ ПОТРЕБЛЕНИЯ ЛЕКАРСТВDRUGS UTILIZATION RESEARCHИспользование топических антибактериальных средств в лечении заболеваний верхних дыхательных путейTopical antibiotics for the treatment of upper respiratory tract diseasesЛясоцкаяЕ. В.LyasotskayaE. V.

Лясоцкая Екатерина Валерьевна — студент

Москва

Ekaterina  V.  Lyasotskaya  — student

Moscow

https://orcid.org/0000-0001-5769-0450СтрокА. Б.StrokA. B.

Строк Алина Борисовна  — к. м. н., ассистент кафедры общей и  клинической фармакологии

Москва

Alina B. Strok  — PhD, Cand. Sci. (Med), Assistant of the Department of General and Clinical Pharmacology

Moscow

strok-ab@rudn.ruФГАОУ ВО «Российский университет дружбы народов имени Патриса Лумумбы»РоссияPeoples' Friendship University of Russia named after Patrice LumumbaRussian Federation202401122024038083Copyright © Лясоцкая Е.В., Строк А.Б., 20242024Лясоцкая Е.В., Строк А.Б.Lyasotskaya E.V., Strok A.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/746Актуальность

Актуальность. Проблема антибиотикорезистентности включает необоснованное использование топических антибактериальных средств.

Цель

Цель: изучить частоту применения топических и системных антибактериальных препаратов среди взрослых, имеющих симптомы заболеваний ЛОР-органов за последние 6 месяцев и роль врача в назначении антибактериальных препаратов.

Методы

Методы: онлайн анкетирование взрослых. Проанализированы данные опроса 111 респондентов старше 18 лет. Выделена группа (61 из 111) респондентов (54,96%), испытывающих симптомы заболевания ЛОР-органов и использующая лекарственные препараты за 6 месяцев до проведения опроса.

Результаты

Результаты: 31,15% респондентов принимали системные антибиотики. Из всех опрошенных, получавших системно антибактериальный препарат, лишь 14 человек из 19 (73,68%) принимали его по назначению врача, 1 (2,38%) по рекомендации фармацевта. При этом все топические антибактериальные препараты — 4 случая (6,6%) респонденты использовали без рекомендации врача или фармацевта.

Заключение

Заключение. Распространённость применения топических антибактериальных препаратов при лечении заболеваний верхних дыхательных путей среди исследуемой группы лиц небольшая, однако высока частота их использования без назначения специалиста.

Actuality

Actuality. Antibiotic resistance includes the unjustified use of topical antibacterial agents.

Objective

Objective. To study the frequency of topical and systemic antibacterial drugs among adults with symptoms of otorhinolaryngological diseases over the past 6 months and the role of physicians in prescribing antibacterial drugs.

Methods

Methods: online questioning of adults. The data from a survey of 111 respondents aged over 18 years were analyzed. A group (61 out of 111) of respondents (54.96%) experiencing symptoms of otorhinolaryngological diseases and using medications 6 months before the survey was conducted was identified.

Results

Results: 31.15% of respondents took systemic antibiotics. Of all respondents who received a systemic antibacterial drug, only 14 out of 19 (73.68%) took it as prescribed by a physician and 1 (2.38%) was prescribed by a pharmacist. At the same time, the respondents used all topical antibacterial drugs — 4 cases (6.6%) without the recommendation of a physician or pharmacist.

Conclusion

Conclusion. The prevalence of topical antibacterial drugs for the treatment of upper respiratory tract diseases among the study population was low, but the frequency of their use without the appointment of a specialist was high.

топические антибиотикисистемные антибиотикиtopical antibioticssystemic antibioticsReferencesSchenck LP, Surette MG, Bowdish DM. Composition and immunological significance of the upper respiratory tract microbiota. FEBS Lett. 2016 Nov;590(21):3705-3720. doi: 10.1002/1873-3468.12455.Schenck LP, Surette MG, Bowdish DM. Composition and immunological significance of the upper respiratory tract microbiota. FEBS Lett. 2016 Nov;590(21):3705-3720. doi: 10.1002/1873-3468.12455.Tai J, Han MS, Kwak J, Kim TH. Association Between Microbiota and Nasal Mucosal Diseases in terms of Immunity. Int J Mol Sci. 2021 Apr 29;22(9):4744. doi: 10.3390/ijms22094744.Tai J, Han MS, Kwak J, Kim TH. Association Between Microbiota and Nasal Mucosal Diseases in terms of Immunity. Int J Mol Sci. 2021 Apr 29;22(9):4744. doi: 10.3390/ijms22094744.Hopkins C, Williamson E, Morris S, et al. Antibiotic usage in chronic rhinosinusitis: analysis of national primary care electronic health records. Rhinology. 2019 Dec 1;57(6):420-429. doi: 10.4193/Rhin19.136.Hopkins C, Williamson E, Morris S, et al. Antibiotic usage in chronic rhinosinusitis: analysis of national primary care electronic health records. Rhinology. 2019 Dec 1;57(6):420-429. doi: 10.4193/Rhin19.136.Овчинников А.Ю., Мирошниченко Н.А., Савранская К.В., Николаева Ю.О. Рациональная местная терапия неосложненного риносинусита как основа успешного выздоровления. Медицинский совет. 2021;(6):21-27.Ovchinnikov AY, Miroshnichenko NA, Savranskaya KV, Nikolaeva YO. Rational topical treatment of uncomplicated rhinosinusitis as a basis for successful recovery. Meditsinskiy sovet = Medical Council. 2021;(6):21-27. (In Russ.) doi: 10.21518/2079-701X-2021-6-21-27.Maxfield AZ, Korkmaz H, Gregorio LL, et al. General antibiotic exposure is associated with increased risk of developing chronic rhinosinusitis. Laryngoscope. 2017 Feb;127(2):296-302. doi: 10.1002/lary.26232.Maxfield AZ, Korkmaz H, Gregorio LL, et al. General antibiotic exposure is associated with increased risk of developing chronic rhinosinusitis. Laryngoscope. 2017 Feb;127(2):296-302. doi: 10.1002/lary.26232.Ni J, Friedman H, Boyd BC, et al. Early antibiotic exposure and development of asthma and allergic rhinitis in childhood. BMC Pediatr. 2019 Jul 5;19(1):225. doi: 10.1186/s12887-019-1594-4.Ni J, Friedman H, Boyd BC, et al. Early antibiotic exposure and development of asthma and allergic rhinitis in childhood. BMC Pediatr. 2019 Jul 5;19(1):225. doi: 10.1186/s12887-019-1594-4.Mosholder AD, Lee JY, Zhou EH, et al. Long-Term Risk of Acute Myocardial Infarction, Stroke, and Death With Outpatient Use of Clarithromycin: A Retrospective Cohort Study. Am J Epidemiol. 2018 Apr 1;187(4):786-792. doi: 10.1093/aje/kwx319.Mosholder AD, Lee JY, Zhou EH, et al. Long-Term Risk of Acute Myocardial Infarction, Stroke, and Death With Outpatient Use of Clarithromycin: A Retrospective Cohort Study. Am J Epidemiol. 2018 Apr 1;187(4):786-792. doi: 10.1093/aje/kwx319.Schembri S, Williamson PA, Short PM, et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ. 2013 Mar 20;346:f1235. doi: 10.1136/bmj.f1235.Schembri S, Williamson PA, Short PM, et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ. 2013 Mar 20;346:f1235. doi: 10.1136/bmj.f1235.Winkel P, Hilden J, Hansen JF, et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trial. Int J Cardiol. 2015 Mar 1;182:459-65. doi: 10.1016/j.ijcard.2015.01.020.Winkel P, Hilden J, Hansen JF, et al. Clarithromycin for stable coronary heart disease increases all-cause and cardiovascular mortality and cerebrovascular morbidity over 10years in the CLARICOR randomised, blinded clinical trial. Int J Cardiol. 2015 Mar 1;182:459-65. doi: 10.1016/j.ijcard.2015.01.020.Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020 Feb 20;58(Suppl S29):53-95. doi: 10.4193/Rhin20.600.Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020 Feb 20;58(Suppl S29):53-95. doi: 10.4193/Rhin20.600.Orlandi RR, Kingdom TT, Smith TL, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021 Mar;11(3):213-739. doi: 10.1002/alr.22741. Erratum in: Int Forum Allergy Rhinol. 2022 Jul;12(7):974. doi: 10.1002/alr.22987.Orlandi RR, Kingdom TT, Smith TL, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021 Mar;11(3):213-739. doi: 10.1002/alr.22741. Erratum in: Int Forum Allergy Rhinol. 2022 Jul;12(7):974. doi: 10.1002/alr.22987.Пшенников Д.С., Анготоева И.Б. Принципы медикаментозного лечения острого бактериального риносинусита: от доказательной медицины к практике. Российский медико-биологический вестник имени академика И.П. Павлова. 2018;26(1):106-116.Pshennikov DS, Angotoeva IB. Principles of drug therapy for acute bacterial rhinosinusitis: from evidence-based medicine to practice. I. P. Pavlov Russian Medical Biological Herald. 2018;26(1):106-116 (In Russ.) doi: 10.23888/PAVLOVJ2018261106-116.Forchhammer J. The in vitro activity of framycetin. Spectrum, sensitivity test and cross resistance. Acta Pathol Microbiol Scand. 1964;60:549-56. doi: 10.1111/apm.1964.60.4.549.Forchhammer J. The in vitro activity of framycetin. Spectrum, sensitivity test and cross resistance. Acta Pathol Microbiol Scand. 1964;60:549-56. doi: 10.1111/apm.1964.60.4.549.Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019 Jan;39(1):10-39. doi: 10.1002/phar.2209.Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019 Jan;39(1):10-39. doi: 10.1002/phar.2209.Woodhouse BM, Cleveland KW. Nebulized antibiotics for the treatment of refractory bacterial chronic rhinosinusitis. Ann Pharmacother. 2011 Jun;45(6):798-802. doi: 10.1345/aph.1P723.Woodhouse BM, Cleveland KW. Nebulized antibiotics for the treatment of refractory bacterial chronic rhinosinusitis. Ann Pharmacother. 2011 Jun;45(6):798-802. doi: 10.1345/aph.1P723.

The authors declare that there are no conflicts of interest present.